TRAX (First Tracks Biotherapeutics) Accounts Payable: $3.79 Mil (As of Dec. 2024)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Accounts Payable?

First Tracks Biotherapeutics TRAX +11.85% 12 Accounts Payable is $3.79 Mil as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

First Tracks Biotherapeutics's Accounts Payable for the quarter that ended in Dec. 2024 was $3.79 Mil.

First Tracks Biotherapeutics's quarterly Accounts Payable increased from . 20 ($0.00 Mil) to Dec. 2023 ($2.43 Mil) and increased from Dec. 2023 ($2.43 Mil) to Dec. 2024 ($3.79 Mil).

First Tracks Biotherapeutics's annual Accounts Payable increased from . 20 ($0.00 Mil) to Dec. 2023 ($2.43 Mil) and increased from Dec. 2023 ($2.43 Mil) to Dec. 2024 ($3.79 Mil).

First Tracks Biotherapeutics Accounts Payable Related Terms

First Tracks Biotherapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Accounts Payable Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Accounts Payable
2.43 3.79

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Accounts Payable 2.43 3.79
TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $3.79 Mil mean?
First Tracks Biotherapeutics (TRAX) has a Accounts Payable of $3.79 Mil as of Dec. 2024. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Accounts Payable too high?
First Tracks Biotherapeutics' current Accounts Payable is $3.79 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Accounts Payable compare to ALT and RGNX?
First Tracks Biotherapeutics' Accounts Payable of $3.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Accounts Payable is $3.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Accounts Payable of $3.79 Mil. The current Accounts Payable is $3.79 Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Accounts Payable is $3.79 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price